Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Yuchen ZhangPan-Pan LiuJun CaiHongmei JingLiqun ZouHuiqiang HuangYuanbin WuWenyu LiLiye ZhongXueli JinXu YeRu FengHuilai ZhangLiling ZhangLie LinXiuhua SunYuyang TianZhongjun XiaZhi-Ming LiHe HuangYi XiaQing-Qing CaiPublished in: Cancer medicine (2022)
Ibrutinib combination therapy demonstrated potentially superior efficacy and comparable tolerability to ibrutinib monotherapy. Ibrutinib-based combination therapy could be one of the prominent treatment options for R/R MCL patients.
Keyphrases
- combination therapy
- chronic lymphocytic leukemia
- end stage renal disease
- newly diagnosed
- ejection fraction
- acute myeloid leukemia
- acute lymphoblastic leukemia
- peritoneal dialysis
- open label
- diffuse large b cell lymphoma
- randomized controlled trial
- clinical trial
- patient reported outcomes
- hodgkin lymphoma
- patient reported